Advertisement
ABBV vs NVS
Which Stock Would AI Choose? AbbVie (ABBV) vs. Novartis (NVS) Stock Comparison
Key Takeaways
- ABBV is delivering double-digit revenue growth led by its immunology franchise, while NVS is navigating the largest patent expiry in its history with low single-digit sales guidance.
- Both are diversified large-cap pharmaceutical leaders, but ABBV carries a "Buy" consensus and premium growth, whereas NVS holds a "Hold" consensus with more range-bound expectations.
- ABBV's momentum is concentrated in Skyrizi and Rinvoq; NVS is more dependent on a broader portfolio including oncology, cardiovascular, and neuroscience assets.
- Recent clinical news moved both names in opposite directions: positive ABBV execution versus a disappointing MS (multiple sclerosis) readout for NVS.
- For more detail on each company's latest developments, visit ABBV Major News and ABBV Today's Price Move, as well as NVS Major News and NVS Today's Price Move.
- To see how automated strategies are currently positioned across the market, explore Trending AI Robots.
Introduction
Investors evaluating large-cap healthcare exposure frequently weigh ABBV against NVS, two of the world's most prominent pharmaceutical franchises. AbbVie and Novartis operate across overlapping therapeutic areas — immunology, oncology, and neuroscience — yet their current market positioning differs meaningfully. This stock comparison is relevant to income-oriented investors, growth seekers, and those focused on relative performance and market positioning within the pharmaceutical sector. By examining recent financial results, pipeline developments, and sentiment shifts, readers can better assess how these two industry leaders compare in the current market environment.
ABBV Overview and Recent Performance
AbbVie (ABBV) is a U.S.-based biopharmaceutical company best known for its immunology franchise, led by blockbuster drugs Skyrizi and Rinvoq, which have successfully offset the decline of its former top seller Humira following biosimilar competition. In recent quarters, the company has reported double-digit revenue growth, with second-quarter 2026 net revenues near $17 billion and adjusted earnings per share (EPS) of $3.65. Skyrizi and Rinvoq each grew more than 20% year over year, while the neuroscience portfolio — including Vraylar and the Parkinson's therapy Vyalev — posted roughly 20% growth.
Sentiment has been supported by raised full-year revenue guidance (now approximately $67.6 billion) and a broadened pipeline through the planned Apogee Therapeutics acquisition. Analysts have lifted price targets into a roughly $260 to $325 range, reflecting confidence in immunology, neuroscience, and oncology assets. However, concentration risk remains a key concern, as Skyrizi and Rinvoq together represent roughly 47% of revenue, and oncology has shown modest declines tied to Imbruvica erosion.
NVS Overview and Recent Performance
Novartis (NVS) is a Swiss-based global pharmaceutical company whose portfolio spans oncology, immunology, neuroscience, and cardiovascular-renal-metabolic diseases. The company has guided for low single-digit sales growth in 2026 while it works through what management has called the largest patent expiry in its history, including generic competition for Entresto and Promacta. Growth drivers such as Kisqali, Kesimpta, Pluvicto, Scemblix, and Leqvio have delivered strong momentum, partly offsetting these losses.
Recent market activity has been mixed. Full late-stage data for remibrutinib, an oral multiple sclerosis candidate, showed relapse-rate reductions below those of Roche's rival pill fenebrutinib, triggering a notable single-day decline in the ADRs (American Depositary Receipts). The company also paused enrollment for an experimental CAR-T (chimeric antigen receptor T-cell) cell therapy after patient deaths. Wall Street maintains a "Hold" consensus with a more range-bound price outlook, though the company's dividend yield near 2% remains a draw for income investors.
Trending AI Robots
Tickeron operates hundreds of AI Trading Bots that collectively trade thousands of different tickers, each built around distinct trading styles, strategies, timeframes, performance statistics, and sets of securities. Given this breadth, only a small selection is considered best suited to prevailing market conditions, and those are featured in the curated Trending AI Robots section. This approach lets traders and investors compare automated strategies across parameters such as risk profile, holding period, and historical performance, rather than relying on a single one-size-fits-all signal. Exploring the current lineup of Trending AI Robots can help you identify the tools most aligned with today's market environment.
Head-to-Head Comparison
In a direct stock comparison, ABBV and NVS diverge most clearly on growth trajectory and lifecycle stage. AbbVie is in a post-Humira reacceleration phase, generating high-teens growth from younger immunology and neuroscience assets, and trades at a forward price-to-earnings ratio around 20, a premium to its own historical average. Novartis, by contrast, is managing a broader but more mature portfolio through a major patent cliff, with more modest near-term revenue growth and a "Hold"-oriented analyst base.
Risk profiles also differ. AbbVie's concentration in two key immunology drugs and upcoming loss-of-exclusivity exposures (into the early 2030s) are notable, while Novartis faces nearer-term generic erosion and recent pipeline setbacks in multiple sclerosis and cell therapy. Both carry currency and regulatory exposures, but their relative positioning reflects AbbVie's stronger current revenue momentum versus Novartis's steadier, dividend-supported profile.
Tickeron AI Verdict
Based on observable factors, Tickeron's AI would likely favor ABBV over NVS in the current environment. The bias stems from AbbVie's more consistent top-line momentum, upward earnings revisions, and clearer near-term catalysts in its immunology and neuroscience franchises, versus Novartis's more cautious guidance and recent clinical disappointments. This assessment reflects relative trend consistency and positioning rather than a definitive forecast, and the balance could shift as pipeline readouts and patent-exposure dynamics evolve for both companies.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ABBV is a Hold and NVS is a Hold.
ABBV saw its Stochastic Oscillator recovers from the overbought zone
The Stochastic Oscillator for ABBV moved out of overbought territory on November 03, 2026. This could be a bearish sign for the stock and investors may want to consider selling or taking a defensive position. A.I.dvisor looked at 69 similar instances where the indicator exited the overbought zone. In 35 of the 69 cases the stock moved lower. This puts the odds of a downward move at 51%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for ABBV moved out of overbought territory on November 02, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 43 similar instances where the indicator moved out of overbought territory. In 17 of the 43 cases, the stock moved lower in the following days. This puts the odds of a move lower at 40%.
The Moving Average Convergence Divergence Histogram (MACD) for ABBV turned negative on November 03, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 48 similar instances when the indicator turned negative. In 20 of the 48 cases the stock turned lower in the days that followed. This puts the odds of success at 42%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ABBV declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 46%.
ABBV broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on November 04, 2026. You may want to consider a long position or call options on ABBV as a result. In 46 of 78 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 59%.
Following a +3.11% 3-day Advance, the price is estimated to grow further. Considering data from situations where ABBV advanced for three days, in 217 of 356 cases, the price rose further within the following month. The odds of a continued upward trend are 61%.
The Aroon Indicator entered an Uptrend today. In 224 of 351 cases where ABBV Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 64%.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 1 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 2 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 59, placing this stock better than average.
The Tickeron Valuation Rating of 4 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: ABBV's P/B Ratio (-86.736) is very low in comparison to the industry average of (-1.360). ABBV has a moderately high P/E Ratio (82.291) as compared to the industry average of (21.695). Projected Growth (PEG Ratio) (0.544) is also within normal values, averaging (5.738). Dividend Yield (0.024) settles around the average of (0.038) among similar stocks. ABBV's P/S Ratio (7.231) is slightly higher than the industry average of (4.033).
The Tickeron Price Growth Rating for this company is 8 (best 1 - 100 worst), indicating outstanding price growth. ABBV’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 8 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 91 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
NVS in upward trend: 10-day moving average broke above 50-day moving average on October 22, 2026
The 10-day moving average for NVS crossed bullishly above the 50-day moving average on October 22, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 69%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 14, 2026. You may want to consider a long position or call options on NVS as a result. In 43 of 80 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 54%.
NVS moved above its 50-day moving average on October 15, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +3.80% 3-day Advance, the price is estimated to grow further. Considering data from situations where NVS advanced for three days, in 187 of 339 cases, the price rose further within the following month. The odds of a continued upward trend are 55%.
The Aroon Indicator entered an Uptrend today. In 162 of 318 cases where NVS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 51%.
Bearish Trend Analysis
The 10-day RSI Indicator for NVS moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 37 similar instances where the indicator moved out of overbought territory. In 20 of the 37 cases, the stock moved lower in the following days. This puts the odds of a move lower at 54%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 17 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The 50-day moving average for NVS moved below the 200-day moving average on October 07, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
NVS broke above its upper Bollinger Band on October 20, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is 4 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 59, placing this stock better than average.
The Tickeron PE Growth Rating for this company is 13 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 33 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 40 (best 1 - 100 worst), indicating steady price growth. NVS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 54 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (7.437) is normal, around the industry mean (-1.360). P/E Ratio (24.370) is within average values for comparable stocks, (21.695). Projected Growth (PEG Ratio) (3.441) is also within normal values, averaging (5.738). NVS has a moderately high Dividend Yield (0.117) as compared to the industry average of (0.038). P/S Ratio (4.715) is also within normal values, averaging (4.033).
ABBV | NVS | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 92 | 36 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 4 Undervalued | 54 Fair valued | |
PROFIT vs RISK RATING 1..100 | 2 | 4 | |
SMR RATING 1..100 | 1 | 33 | |
PRICE GROWTH RATING 1..100 | 8 | 40 | |
P/E GROWTH RATING 1..100 | 91 | 13 | |
SEASONALITY SCORE 1..100 | 8 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ABBV's Valuation (4) in the Pharmaceuticals Major industry is somewhat better than the same rating for NVS (54). This means that ABBV’s stock grew somewhat faster than NVS’s over the last 12 months.
ABBV's Profit vs Risk Rating (2) in the Pharmaceuticals Major industry is in the same range as NVS (4). This means that ABBV’s stock grew similarly to NVS’s over the last 12 months.
ABBV's SMR Rating (1) in the Pharmaceuticals Major industry is in the same range as NVS (33). This means that ABBV’s stock grew similarly to NVS’s over the last 12 months.
ABBV's Price Growth Rating (8) in the Pharmaceuticals Major industry is in the same range as NVS (40). This means that ABBV’s stock grew similarly to NVS’s over the last 12 months.
NVS's P/E Growth Rating (13) in the Pharmaceuticals Major industry is significantly better than the same rating for ABBV (91). This means that NVS’s stock grew significantly faster than ABBV’s over the last 12 months.
| ABBV | NVS | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 40% | 1 day ago 54% |
| Stochastic ODDS (%) | 1 day ago 51% | 1 day ago 38% |
| Momentum ODDS (%) | 1 day ago 59% | 1 day ago 54% |
| MACD ODDS (%) | 1 day ago 42% | N/A |
| TrendWeek ODDS (%) | 1 day ago 49% | 1 day ago 56% |
| TrendMonth ODDS (%) | 1 day ago 64% | 1 day ago 51% |
| Advances ODDS (%) | 9 days ago 61% | 12 days ago 55% |
| Declines ODDS (%) | 5 days ago 46% | N/A |
| BollingerBands ODDS (%) | 1 day ago 41% | 1 day ago 30% |
| Aroon ODDS (%) | 1 day ago 64% | 1 day ago 51% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ABBV’s FA Score shows that 4 FA rating(s) are green while NVS’s FA Score has 3 green FA rating(s).
- ABBV’s FA Score: 4 green, 1 red.
- NVS’s FA Score: 3 green, 2 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ABBV’s TA Score shows that 3 TA indicator(s) are bullish while NVS’s TA Score has 5 bullish TA indicator(s).
- ABBV’s TA Score: 3 bullish, 5 bearish.
- NVS’s TA Score: 5 bullish, 4 bearish.
Price Growth
ABBV (@Pharmaceuticals: Major) experienced а -1.21% price change this week, while NVS (@Pharmaceuticals: Major) price change was +1.09% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -0.85%. For the same industry, the average monthly price growth was -1.19%, and the average quarterly price growth was +4.39%.
Reported Earning Dates
ABBV is expected to report earnings on Feb 03, 2027.
NVS is expected to report earnings on Feb 03, 2027.
Industries' Descriptions
@Pharmaceuticals: Major (-0.85% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
Advertisement
ABBV and
Correlation & Price change
A.I.dvisor indicates that over the last year, ABBV has been loosely correlated with NVS. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if ABBV jumps, then NVS could also see price increases.
| Ticker / NAME | Correlation To ABBV | 1D Price Change % | ||
|---|---|---|---|---|
| ABBV | 100% | +1.07% | ||
| NVS - ABBV | 52% Loosely correlated | +0.38% | ||
| JNJ - ABBV | 51% Loosely correlated | +1.43% | ||
| BMY - ABBV | 50% Loosely correlated | -1.57% | ||
| AMGN - ABBV | 49% Loosely correlated | +0.03% | ||
| GILD - ABBV | 47% Loosely correlated | -0.41% | ||
More | ||||
NVS and
Correlation & Price change
A.I.dvisor indicates that over the last year, NVS has been loosely correlated with GSK. These tickers have moved in lockstep 64% of the time. This A.I.-generated data suggests there is some statistical probability that if NVS jumps, then GSK could also see price increases.